Literature DB >> 10234507

Rapid and efficient ATM mutation detection by fluorescent chemical cleavage of mismatch: identification of four novel mutations.

L Izatt1, C Vessey, S V Hodgson, E Solomon.   

Abstract

Mutations in the Ataxia Telangiectasia Mutated (ATM) gene are responsible for the autosomal recessive disease Ataxia Telangiectasia (A-T). A wide variety of mutations scattered across the entire coding region (9168bp) of ATM have been found, which presents a challenge in developing an efficient mutation screening strategy for detecting unknown mutations. Fluorescent chemical cleavage of mismatch (FCCM) is an ideal mutation screening method, offering a non-radioactive alternative to other techniques such as restriction endonuclease fingerprinting (REF). Using FCCM, we have developed an efficient, accurate and sensitive mutation detection method for screening RT-PCR products for ATM mutations. We have identified seven ATM mutations in five A-T families, four of which are previously unknown. We quantified ATM protein expression in four of the families and found variable ATM protein expression (0-6.4%), further evidence for mutant ATM protein expression in both classic and variant A-T patients. We conclude that FCCM offers a robust ATM mutation detection method and can be used to screen for ATM mutations in cancer-prone populations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10234507     DOI: 10.1038/sj.ejhg.5200288

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  2 in total

1.  Autosomal recessive spinocerebellar ataxia and peripheral neuropathy with raised alpha-fetoprotein.

Authors:  Louise Izatt; Andrea H Németh; Anjela Meesaq; Kerry R Mills; A Malcolm R Taylor; Christopher E Shaw
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

Review 2.  Multifunctional role of ATM/Tel1 kinase in genome stability: from the DNA damage response to telomere maintenance.

Authors:  Enea Gino Di Domenico; Elena Romano; Paola Del Porto; Fiorentina Ascenzioni
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.